# EDGAR Filing Document

**Accession Number:** 0001756770
**File Stem:** 0001756770-25-000025
**Filing Date:** 2025-7
**Character Count:** 4967
**Document Hash:** ff1b60995a13ae40416535530c195d19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001756770-25-000025.hdr.sgml**: 20250708

**ACCESSION NUMBER**: 0001756770-25-000025

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20250708

**FILED AS OF DATE**: 20250708

**DATE AS OF CHANGE**: 20250708

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Curaleaf Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001756770
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 333-249081
- **FILM NUMBER:** 251110681

**BUSINESS ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170
- **BUSINESS PHONE:** 781-451-0117

**MAIL ADDRESS:**
- **STREET 1:** 420 LEXINGTON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10170

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEAD VENTURES INC.
- **DATE OF NAME CHANGE:** 20181023

**UNITED STATES<br>SECURITIES AND EXCHANGE COMMISSION <br>Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER <br>THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July, 2025**

**Commission File Number: 333-249081**

**<u>Curaleaf Holdings, Inc.</u>**<br> (Name of Registrant)

**666 Burrard Street, Suite 1700,** 

**Vancouver, British Columbia V6C 2X8, Canada**<br>(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☐&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F ☒

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **CURALEAF HOLDINGS, INC.** | **CURALEAF HOLDINGS, INC.** |
| | | (Registrant) | (Registrant) |
| Date: | July 8, 2025 | By: | */s/ Peter Clateman* |
|  |  | Name: | Peter Clateman |
|  |  | Title: | Chief Legal Officer |

---

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| [99.1](pressrelease7825cihl.htm) | [Press Release](pressrelease7825cihl.htm) |

---

## Exhibit 99.1

![](pressrelease7825cihl001.jpg)

------

![](pressrelease7825cihl002.jpg)

phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward- looking statements and information concerning the expected benefits of the acquisition on the European business and operations of Curaleaf, and the listing of shares issuable in connection with the acquisition on the Toronto Stock Exchange. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matters described in this new release, including the Company's ability to successfully realize the expected benefits of the acquisition, and the Company's ability to fulfill the listing conditions imposed by the Toronto Stock Exchange. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including the failure to realize the expected benefits of the acquisition. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors" the Company's Annual Information Form dated March 3, 2025 for the fiscal year ended December 31, 2024, and as described from time to time in documents filed by the Company with Canadian securities regulatory authorities. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward- looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Toronto Stock Exchange has not reviewed, approved or disapproved of the content of this news release. Investor Contact: Curaleaf Holdings, Inc. Camilo Lyon, Chief Investment Officer IR@curaleaf.com Media Contact: Curaleaf Holdings, Inc. Jordon Rahmil, VP Public Relations media@curaleaf.com SOURCE Curaleaf Holdings, Inc. https://ir.curaleaf.com/2025-07-08-Curaleaf-Holdings-Announces-Buyout-of-Minority-Partner-in-Curaleaf- International

------